Topics
CME/CE
Editorial Board
Raptiva Rolls Out
San Francisco ?? Sources familiar with Raptiva (efalizumab) hail its approval by the U.S. Food and Drug Administration last month as nothing but an enhancement to patient compliance and successful treatment of chronic moderate-to-severe plaque psoriasis.
Related Videos
Related Content
